Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Improving Function in Age-Related Macular Degeneration
Authors not listed
Thomas Jefferson University · 2005
Abstract
This randomized, controlled clinical trial will test the efficacy of Problem-Solving Treatment (PST) to improve vision function in older persons with age-related macular degeneration (AMD). AMD is a highly prevalent, disabling disease of aging that causes severe vision loss and functional decline. It is the leading cause of blindness in older persons in the United States and may affect more than 10 million people. Currently, there are no effective treatments to restore vision. Thus, improving Vision Function is a major goal of treatment. Vision function refers to vision-related abilities to perform daily living activities (e.g. reading recipes to prepare meals). Decrements in vision function will become a major public health problem as the population ages and the prevalence of AMD increases. PST is a brief, standardized, cognitive-behavioral treatment that teaches problem-solving skills.
We believe PST will enable patients with AMD find practical solutions to vision-related problems and thereby improve vision function.
We will recruit 240 AMD patients from the retina clinics of Wills Eye Institute, Philadelphia, PA, with bilateral AMD and visual acuity worse than 20/70 in the better eye. PST-trained therapists will deliver 6 1-hour, in-home sessions to the 120 subjects randomized to PST. The control treatment is Supportive Therapy (ST), a similarly structured, standardized psychological treatment that controls for the non-specific effects of treatment (n=120). ST contains no active elements beyond its non-specific components; in this way it is a placebo treatment. Independent raters, masked to treatment assignment, will assess Targeted Vision Function (primary outcome) and vision-related quality of life (secondary outcome) at 3 months to assess PST's efficacy, and at 6 months to evaluate its long-term effects. As the population ages, the disability of AMD will become more prevalent, costly, and burdensome to patients, families, and ophthalmologists. This makes devising and testing practical and affordable interventions to improve vision function a national priority.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-08 MST
Cite this
APA
Anonymous. (2005). Improving Function in Age-Related Macular Degeneration. <em>Thomas Jefferson University</em>. https://clinicaltrials.gov/study/NCT00572039
Vancouver
Anonymous. Improving Function in Age-Related Macular Degeneration. Thomas Jefferson University. 2005.
BibTeX
@misc{anon2005Improv,
title = {Improving Function in Age-Related Macular Degeneration},
author = {Anonymous},
journal = {Thomas Jefferson University},
year = {2005},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Odense University Hospital 2022
Open access · US-GOV
Improving Quality of Life in Frail, Older Patients with Hematological Cancer Through Geriatric Assessment and Treatment - a Pilot Study
Community Eye Health Journal 2014
Open access · CC-BY
Age-related macular degeneration
Zhejiang Provincial Tongde Hospital 2026
Open access · US-GOV
A Prospective, Single-Arm Study Evaluating Silkworm Pupa Powder in Improving Alzheimer's Disease Among Patients
International Journal of Molecular Sciences 2021
Open access · CC-BY
Mesenchymal Stem Cell Transplantation for the Treatment of Age-Related Musculoskeletal Frailty
Science Corporation 2020
Open access · US-GOV
Restoration of Central Vision With the PRIMA System in Patients With Atrophic Age-Related Macular Degeneration
Archives of Ophthalmology 2002
Open access · OA